Stockscreener 앱 받기
0.5278
3.61%
0.0184
시간 외 거래:
.54
0.0122
+2.31%
전일 마감가:
$0.5094
열려 있는:
$0.52
하루 거래량:
796.21K
Relative Volume:
0.48
시가총액:
$52.87M
수익:
-
순이익/손실:
$-30.54M
주가수익비율:
-0.2666
EPS:
-1.98
순현금흐름:
$-18.30M
1주 성능:
+17.81%
1개월 성능:
+21.42%
6개월 성능:
-49.25%
1년 성능:
+5.14%
1일 변동 폭
$0.50
$0.536
1주일 범위
$0.4191
$0.5461
52주 변동 폭
$0.202
$1.818
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| UNCY | 0.5278 | 52.87M | 0 | -30.54M | -18.30M | -1.98 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Unicycive Therapeutics to Participate in Two Upcoming - GlobeNewswire
Unicycive Therapeutics CEO to Present at Noble Capital and Piper Sandler Healthcare Conferences | UNCY Stock News - StockTitan
Logos Global Management LP Adjusts Stake in Unicycive Therapeuti - GuruFocus.com
RA Capital Management's Strategic Acquisition of Unicycive Thera - GuruFocus.com
Great Point Partners LLC's Strategic Investment in Unicycive The - GuruFocus.com
Walleye Capital LLC Acquires New Stake in Unicycive Therapeutics Inc - GuruFocus.com
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Unicycive's OLC Drug Gets FDA Review Date, Reports Strong Q3 Pipeline Progress | UNCY Stock News - StockTitan
USFDA accepts Shilpa Medicare CDMO partner Unicycive NDA for Oxylanthanum Carbonate - Medical Dialogues
Unicycive Therapeutics (NASDAQ:UNCY) Given Buy Rating at HC Wainwright - MarketBeat
Unicycive shares hold as FDA accepts NDA for kidney treatment By Investing.com - Investing.com UK
Shilpa Medicare update on its CDMO partnerUnicycive Therapeutics - Business Standard
Unicycive shares hold as FDA reviews new drug application By Investing.com - Investing.com UK
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Marketscreener.com
Unicycive eyes June FDA verdict for hyperphosphataemia drug - pharmaphorum
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia - MarketWatch
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The Manila Times
Unicycive Therapeutics Announces U.S. FDA Acceptance of the - GlobeNewswire
Unicycive's Kidney Disease Drug Gets FDA Review Date, Aims for 2025 Launch | UNCY Stock News - StockTitan
Thinking about buying stock in Beyondspring, LAVA Therapeutics, - GuruFocus.com
Unicycive Therapeutics Delivers Multiple Poster - GlobeNewswire
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - StockTitan
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - StockTitan
This trade activity should not be overlooked: Unicycive Therapeutics Inc (UNCY) - SETE News
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near? - Simply Wall St
A year in review: Unicycive Therapeutics Inc (UNCY)’s performance in the last year - US Post News
Unicycive to present kidney disease therapies at ASN Kidney Week - Investing.com
Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.37, Up 3.12 - The Dwinnex
Unicycive to present kidney disease therapies at ASN Kidney Week By Investing.com - Investing.com South Africa
UNCYUnicycive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Unicycive Therapeutics Announces Late-Breaker Poster - GlobeNewswire
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41 - MSN
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc - Yahoo Finance
Octagon Capital Advisors LP Acquires New Stake in Unicycive Ther - GuruFocus.com
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
Unicycive reports successful phase 1 kidney drug trial - Investing.com
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - The Manila Times
Unicycive reports successful phase 1 kidney drug trial By Investing.com - Investing.com UK
Unicycive Therapeutics Inc (UNCY) is looking forward to a strong quarter - SETE News
UNCY’s earnings forecast for the current quarter - US Post News
Ratio Analysis: Unpacking Unicycive Therapeutics Inc (UNCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Unicycive Therapeutics Inc: Weathering Stock Market Storms with 35.62M Market Cap - The InvestChronicle
Get in on Unicycive Therapeutics Inc’s (UNCY) buy-in window today! - SETE News
Unicycive Therapeutics' SWOT analysis: stock potential in kidney disease market - Investing.com
Was anything positive for Unicycive Therapeutics Inc (UNCY) stock last session? - US Post News
What is Unicycive Therapeutics Inc (UNCY) Stock Return on Shareholders’ Capital? - SETE News
Market Recap Check: Unicycive Therapeutics Inc (UNCY)’s Positive Finish at 0.44, Up/Down 2.82 - The Dwinnex
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - ForexTV.com
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.56%
자본화:
|
볼륨(24시간):